Eli Lilly's Once-Weekly Insulin Wins FDA Approval, Ending Daily Shot Era for Millions

The FDA approved Eli Lilly's Onswik, the first-ever once-weekly basal insulin injection for type 2 diabetes, eliminating the burden of daily shots for millions of patients. The approval, announced Wednesday, is backed by the QWINT Phase 3 programme — four clinical trials enrolling more than 3,400 adults with type 2 diabetes — and sets up a direct commercial clash with Novo Nordisk, whose daily insulins currently dominate the market. For the estimated **500 million...